Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Park, Byeong-Bae | - |
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Kim, Sang We | - |
dc.contributor.author | Kim, Heung-Tae | - |
dc.contributor.author | Lee, Jong Seog | - |
dc.contributor.author | Kang, Jin Hyung | - |
dc.contributor.author | Cho, Jae Yong | - |
dc.contributor.author | Song, Hong Suk | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Sohn, Chang Hak | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Choi, Jin Hyuck | - |
dc.contributor.author | Ki, Chang-Seok | - |
dc.contributor.author | Park, Chan Keum | - |
dc.contributor.author | Holmes, Alison J. | - |
dc.contributor.author | Janne, Pasi A. | - |
dc.contributor.author | Park, Keunchil | - |
dc.date.accessioned | 2022-10-07T10:27:23Z | - |
dc.date.available | 2022-10-07T10:27:23Z | - |
dc.date.created | 2022-08-26 | - |
dc.date.issued | 2008-06 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/172030 | - |
dc.description.abstract | Purpose: This study investigated possible molecular predictors of outcome in Korean patients with advanced non-small cell lung cancer treated with erlotinib. Experimental Design: One hundred and twenty patients received erlotinib and were followed prospectively. Ninety-two tissue samples were analyzed for epidermal growth factor receptor (EGFR) gene mutations (exons 18, 19, and 21), 88 for EGFR gene amplification by real-time PCR, and 75 for EGFR protein expression by immunohistochemistry. Results: The overall tumor response rate was 24.2% (complete response, 4; partial response, 25) with 56.7% of disease control rate. With a median follow-up of 23.6 months, the median time to progression (TTP) was 2.7 months and the median overall survival was 12.9 months. EGFR gene mutations were found in 26.1% (24 of 92), EGFR gene amplification in 40.9% (36 of 88), and EGFR protein expression in 72% (54 of 75). There was a strong association between EGFR gene mutations and gene amplification (gamma = 0.241). Patients with EGFR gene mutations or gene amplification showed both better response rate (58.3% versus 16.2%, P < 0.001; 41.7% versus 17.3%, P = 0.012) and TTP (8.6 versus 2.5 months, P = 0.003; 5.8 versus 1.8 months, P < 0.001) and overall survival (not reached versus 10.8 months, P = 0.023; not reached versus 10.1 months, P = 0.033). By multivariate analysis, EGFR gene mutation was the only significant molecular predictor for TTP (hazard ratio, 0.47; 95% confidence interval, 0.25-0.89). Conclusions: Our findings indicate that EGFR gene mutation is a more predictive marker for improved TTP than EGFR gene amplification in erlotinib-treated Korean non-small cell lung cancer patients. Prospective studies from diverse ethnic backgrounds are required to determine the exact role of these molecular markers. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.title | Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Byeong-Bae | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-07-4608 | - |
dc.identifier.scopusid | 2-s2.0-52449091935 | - |
dc.identifier.wosid | 000256779100032 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, v.14, no.12, pp.3860 - 3866 | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.citation.title | CLINICAL CANCER RESEARCH | - |
dc.citation.volume | 14 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 3860 | - |
dc.citation.endPage | 3866 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | FACTOR-RECEPTOR GENE | - |
dc.subject.keywordPlus | GEFITINIB SENSITIVITY | - |
dc.subject.keywordPlus | EGFR MUTATIONS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.identifier.url | https://aacrjournals.org/clincancerres/article/14/12/3860/72740/Are-There-Any-Ethnic-Differences-in-Molecular | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.